Aptevo Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aptevo Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2015 to Q2 2024.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $273K, a 41.3% decline year-over-year.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $1.81M, a 13.9% decline year-over-year.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.19M, a 21.7% increase from 2022.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.8M, a 9.68% increase from 2021.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.64M, a 30.9% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.81M $273K -$192K -41.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $2M $719K -$196K -21.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $2.19M $358K $0 0% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $2.19M $455K +$96K +26.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $2.1M $465K -$19K -3.93% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $2.12M $915K +$314K +52.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $1.8M $358K +$180K +101% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $1.62M $359K +$40K +12.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $1.58M $484K -$88K -15.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $1.67M $601K +$27K +4.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $1.64M $178K -$20K -10.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $1.66M $319K -$24K -7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.69M $572K +$271K +90% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $1.42M $574K +$161K +39% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $1.26M $198K -$71K -26.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $1.33M $343K +$9K +2.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $1.32M $301K -$100K -24.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $1.42M $413K -$181K -30.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $1.6M $269K -$224K -45.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $1.82M $334K -$147K -30.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $1.97M $401K -$48K -10.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $2.02M $594K -$123K -17.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 $2.14M $493K -$573K -53.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-25
Q3 2018 $2.71M $481K -$559K -53.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $3.27M $449K -$651K -59.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $3.92M $717K -$961K -57.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $4.88M $1.07M +$1.68M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $3.2M $1.04M -$293K -22% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 $3.49M $1.1M +$700K +175% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $2.79M $1.68M -$1.02M -37.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $3.81M -$617K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-13
Q3 2016 $1.33M +$1.05M +374% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $400K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $2.69M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q3 2015 $281K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.